Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10387783 | 0.86 | ADRB1 (0.50) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL10479117 | 0.85 | KDM4E (0.40) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| SCHEMBL14414250 | 0.85 | POLB (0.36) | KDM4EPOLBCYP2B6ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL10388921 | 0.84 | LMNA (0.51) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL10388040 | 0.84 | LMNA (0.51) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| SCHEMBL27991480 | 0.83 | ADRB1 (0.37) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| SCHEMBL4396491 | 0.82 | POLB (0.50) | TSHRPOLBHSD11B1HPGD | |
| Hydrochloric Acid SCHEMBL11643074 | 0.78 | HDAC1 (0.35) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| SCHEMBL11639419 | 0.76 | DPP4 (0.32) | ADRB1LMNAADRB2HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL11642403 | 0.76 | ADRB2 (0.44) | ADRB1LMNAADRB2HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2012-08-30 | — | — | US | claimed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | claimed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | claimed |
| EP-1993525-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | claimed |
| WO-2007102008-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | claimed |
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | SOSEI R&D LTD. (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1993525-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| EP-1896393-A1 | THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007102008-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007003896-A1 | THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, HRH2 | ADRB1 36/4885LMNA 3116/4885ADRB2 19/4885 |
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | HRH3, OPRL1, HRH2 | ADRB1 198/4885LMNA 3411/4885ADRB2 131/4885 |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, NR1H2 | ADRB1 13/4885LMNA 2869/4885ADRB2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.